If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and ...

This is 40-something. Kim Kardashian, 45, has tried to cling to her youth by undergoing skin-tightening treatments, traveling ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive ...

January might offer a new year reset, but chronic illness demands us to move forward and bring what we’ve learned, says ...

The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

Shopper News brings you the latest happenings in your community ...

Cosentyx (secukinumab) is a prescription drug used to treat certain types of arthritis and other conditions. The drug comes as a liquid solution inside single-use pens, syringes, and vials. It may be ...